Literature DB >> 16185603

Early stage breast cancer conserving treatment: high dose rate brachytherapy boost to the tumour bed.

María Concepción López Carrizosa1, Pilar María Samper Ots, Carmen Vallejo Ocaña, Aurora Rodríguez Pérez, Juan de Dios Sáez Garrido, José María Delgado Pérez.   

Abstract

INTRODUCTION: The dose administered to the tumour bed is a risk-factor for local recurrence in localised breast cancer following breast-conserving surgery.
MATERIALS AND METHODS: All patients (n=94) received 50 Gy external beam radiotherapy and one application of 700 cGy at 85% isodose with high dose rate brachytherapy.
RESULTS: Of the cases, 84% were infiltrating ductal carcinoma; 31.2% were G3; 28% were intraductal component > 25%; 54% had margin < 1 cm or unknown. With a mean follow-up of 65 months (range: 36-107 months), the overall actuarial survival at 5 and 8 years was 93.2% and 84.2%, respectively; disease-free survival was 88.3% and 84.6%, respectively; local control was 92.2% and 88.75%, respectively. Local recurrence rate was 5.3%, and distant dissemination rate was 8.5%. Among the risk-factors analysed, only the presence of 4 or more lymph node involvement implied a higher risk for local recurrence (p =0.0001). For distant dissemination, the risk-factors were: 4 or more lymph nodes involved (p = 0.0001),G3 (p =0.029), tumour >3 cm (p = 0.001), irradiation volume with external beam radiotherapy (p =0.0001), and presence of local recurrence (p = 0.001).
CONCLUSION: High dose rate brachytherapy is an effective method for reducing local recurrence, and increasing local control.

Entities:  

Mesh:

Year:  2005        PMID: 16185603     DOI: 10.1007/bf02716550

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  43 in total

Review 1.  Local resection and brachytherapy confined to the lumpectomy site for early breast cancer: a pilot study.

Authors:  F Perera; J Engel; R Holliday; L Scott; M Girotti; D Girvan; F Chisela; V Venkatesan
Journal:  J Surg Oncol       Date:  1997-08       Impact factor: 3.454

Review 2.  Brachytherapy and breast cancer.

Authors:  J R White; J F Wilson
Journal:  Semin Surg Oncol       Date:  1997 May-Jun

3.  Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06.

Authors:  E R Fisher; S Anderson; E Tan-Chiu; B Fisher; L Eaton; N Wolmark
Journal:  Cancer       Date:  2001-04-15       Impact factor: 6.860

4.  High-dose-rate brachytherapy for early breast cancer: an ambulatory technique.

Authors:  C Hennequin; C Durdux; M Espié; S Balla-Mekias; M Housset; M Marty; G Chotin; C Maylin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-08-01       Impact factor: 7.038

5.  Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.

Authors:  J A Jacobson; D N Danforth; K H Cowan; T d'Angelo; S M Steinberg; L Pierce; M E Lippman; A S Lichter; E Glatstein; P Okunieff
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

6.  Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials.

Authors: 
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

7.  Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002.

Authors:  P Wallner; D Arthur; H Bartelink; J Connolly; G Edmundson; A Giuliano; N Goldstein; J Hevezi; T Julian; R Kuske; A Lichter; B McCormick; R Orecchia; L Pierce; S Powell; L Solin; F Vicini; T Whelan; J Wong; C N Coleman
Journal:  J Natl Cancer Inst       Date:  2004-02-04       Impact factor: 13.506

8.  Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy.

Authors:  Funda Meric; Nadeem Q Mirza; Georges Vlastos; Thomas A Buchholz; Henry M Kuerer; Gildy V Babiera; S Eva Singletary; Merrick I Ross; Frederick C Ames; Barry W Feig; Savitri Krishnamurthy; George H Perkins; Marsha D McNeese; Eric A Strom; Vicente Valero; Kelly K Hunt
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

9.  Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer.

Authors:  D Sarrazin; M G Lê; R Arriagada; G Contesso; F Fontaine; M Spielmann; F Rochard; T Le Chevalier; J Lacour
Journal:  Radiother Oncol       Date:  1989-03       Impact factor: 6.280

10.  Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients.

Authors:  U Veronesi; B Salvadori; A Luini; M Greco; R Saccozzi; M del Vecchio; L Mariani; S Zurrida; F Rilke
Journal:  Eur J Cancer       Date:  1995-09       Impact factor: 9.162

View more
  3 in total

1.  Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma.

Authors:  José Luis Guinot; M Isabel Tortajada; María Carrascosa; Vicente Crispín; Ana Otero; Belén Ríos; Eleonor Rivin; Miguel Santos; Pablo Soler; Leoncio Arribas
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

2.  Conservative surgery, external radiotherapy, and HDR brachytherapy in a single fraction of 7 Gy in early breast cancer: long-term toxicity and esthetic assessment.

Authors:  Aurora Rodríguez Pérez; Maria Concepción López Carrizosa; Pilar Maria Samper Ots; José Fermín Pérez-Regadera Gómez; José Zapatero Ortuño; Juan de Dios Sáez Garrido; Manuel Joaquín Martín de Miguel
Journal:  Clin Transl Oncol       Date:  2012-09-14       Impact factor: 3.405

3.  Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed.

Authors:  Aurora Rodríguez Pérez; Pilar María Samper Ots; María Concepción López Carrizosa; José Fermín Pérez-Regadera Gómez; José Zapatero Ortuño; Juan de Dios Sáez Garrido; Manuel Joaquín Martín de Miguel
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.